Literature DB >> 31430267

Comparison of Self-controlled Designs for Evaluating Outcomes of Drug-Drug Interactions: Simulation Study.

Katsiaryna Bykov1, Jessica M Franklin1, Hu Li2, Joshua J Gagne1.   

Abstract

BACKGROUND: Self-controlled designs, both case-crossover and self-controlled case series, are well suited for evaluating outcomes of drug-drug interactions in electronic healthcare data. Their comparative performance in this context, however, is unknown.
METHODS: We simulated cohorts of patients exposed to two drugs: a chronic drug (object) and a short-term drug (precipitant) with an associated interaction of 2.0 on the odds ratio scale. We analyzed cohorts using case-crossover and self-controlled case series designs evaluating exposure to the precipitant drug within person-time exposed to the object drug. Scenarios evaluated violations of key design assumptions: (1) time-varying, within-person confounding; (2) time trend in precipitant drug exposure prevalence; (3) nontransient precipitant exposure; and (4) event-dependent object drug discontinuation.
RESULTS: Case-crossover analysis produced biased estimates when 30% of patients persisted on the precipitant drug (estimated OR 2.85) and when the use of the precipitant drug was increasing in simulated cohorts (estimated OR 2.56). Self-controlled case series produced biased estimates when patients discontinued the object drug following the occurrence of an outcome (estimated incidence ratio [IR] of 2.09 [50% of patients stopping therapy] and 2.22 [90%]). Both designs yielded similarly biased estimates in the presence of time-varying, within-person confounding.
CONCLUSION: In settings with independent or rare outcomes and no substantial event-dependent censoring (<50%), self-controlled case series may be preferable to case-crossover design for evaluating outcomes of drug-drug interactions. With frequent event-dependent drug discontinuation, a case-crossover design may be preferable provided there are no time-related trends in drug exposure.

Entities:  

Mesh:

Year:  2019        PMID: 31430267      PMCID: PMC6768702          DOI: 10.1097/EDE.0000000000001087

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  15 in total

1.  When should case-only designs be used for safety monitoring of medical products?

Authors:  Malcolm Maclure; Bruce Fireman; Jennifer C Nelson; Wei Hua; Azadeh Shoaibi; Antonio Paredes; David Madigan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01       Impact factor: 2.890

2.  Tutorial in biostatistics: the self-controlled case series method.

Authors:  Heather J Whitaker; C Paddy Farrington; Bart Spiessens; Patrick Musonda
Journal:  Stat Med       Date:  2006-05-30       Impact factor: 2.373

3.  The case-crossover study design in pharmacoepidemiology.

Authors:  Joseph A 'Chris' Delaney; Samy Suissa
Journal:  Stat Methods Med Res       Date:  2008-09-02       Impact factor: 3.021

4.  The methodology of self-controlled case series studies.

Authors:  Heather J Whitaker; Mounia N Hocine; C Paddy Farrington
Journal:  Stat Methods Med Res       Date:  2008-06-18       Impact factor: 3.021

5.  Persistent User Bias in Case-Crossover Studies in Pharmacoepidemiology.

Authors:  Jesper Hallas; Anton Pottegård; Shirley Wang; Sebastian Schneeweiss; Joshua J Gagne
Journal:  Am J Epidemiol       Date:  2016-11-15       Impact factor: 4.897

Review 6.  Pharmacoepidemiologic Methods for Studying the Health Effects of Drug-Drug Interactions.

Authors:  S Hennessy; C E Leonard; J J Gagne; J H Flory; X Han; C M Brensinger; W B Bilker
Journal:  Clin Pharmacol Ther       Date:  2015-11-23       Impact factor: 6.875

7.  The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers.

Authors:  Alissa J Wright; Tara Gomes; Muhammad M Mamdani; John R Horn; David N Juurlink
Journal:  CMAJ       Date:  2011-01-17       Impact factor: 8.262

8.  Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding.

Authors:  H Schelleman; W B Bilker; C M Brensinger; X Han; S E Kimmel; S Hennessy
Journal:  Clin Pharmacol Ther       Date:  2008-08-06       Impact factor: 6.875

9.  Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations.

Authors:  Shirley V Wang; Joshua J Gagne; Robert J Glynn; Sebastian Schneeweiss
Journal:  Epidemiology       Date:  2013-05       Impact factor: 4.822

10.  Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs.

Authors:  Ian J Douglas; Stephen J W Evans; Aroon D Hingorani; Anthony M Grosso; Adam Timmis; Harry Hemingway; Liam Smeeth
Journal:  BMJ       Date:  2012-07-10
View more
  2 in total

1.  Response to "The Self-Controlled Case Series Design as a Viable Alternative to Studying Clinically Relevant Drug Interactions".

Authors:  Katsiaryna Bykov; Joshua J Gagne
Journal:  Clin Pharmacol Ther       Date:  2019-10-21       Impact factor: 6.875

2.  Drug-Drug Interaction Surveillance Study: Comparing Self-Controlled Designs in Five Empirical Examples in Real-World Data.

Authors:  Katsiaryna Bykov; Hu Li; Sangmi Kim; Seanna M Vine; Vincent Lo Re; Joshua J Gagne
Journal:  Clin Pharmacol Ther       Date:  2020-12-17       Impact factor: 6.875

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.